カテゴリ： 世界, 医療/バイオ, QYResearch

エプタコグアルファ（rFVIIa）の世界市場2023年：凍結乾燥製剤、凍結乾燥粉体

■ 英語タイトル：Global Eptacog Alfa (rFVIIa) Market Research Report 2023

調査会社QYResearch社が発行したリサーチレポート（データ管理コード：QYR23MA8754）■ 発行会社/調査会社：QYResearch
■ 商品コード：QYR23MA8754
■ 発行日：2023年3月
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：91
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,900 ⇒換算￥440,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD4,350 ⇒換算￥661,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD5,800 ⇒換算￥881,600見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[エプタコグアルファ（rFVIIa）の世界市場2023年：凍結乾燥製剤、凍結乾燥粉体]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

本調査資料はエプタコグアルファ（rFVIIa）のグローバル市場について調査・分析し、世界のエプタコグアルファ（rFVIIa）市場概要、メーカー別競争状況、地域別市場規模、タイプ別セグメント分析（凍結乾燥製剤、凍結乾燥粉体）、用途別セグメント分析（血友病、後天性血友病、第VII因子欠乏症、グランツマン血栓症（GT））、主要企業のプロファイル、市場動向などに関する情報を掲載しています。主要企業としては、Novo Nordisk、LFB SA、GENERIUM、Northland-bio、CSL、Shire (Takeda)、Bayerなどが含まれています。エプタコグアルファ（rFVIIa）のグローバル市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。新型コロナとロシア・ウクライナ戦争の影響は、エプタコグアルファ（rFVIIa）市場規模を算出する際に考慮しました。

・エプタコグアルファ（rFVIIa）市場の概要
- 製品の定義
- エプタコグアルファ（rFVIIa）の種類別セグメント
- 世界のエプタコグアルファ（rFVIIa）市場規模：タイプ別分析（凍結乾燥製剤、凍結乾燥粉体）
- エプタコグアルファ（rFVIIa）の用途別セグメント
- 世界のエプタコグアルファ（rFVIIa）市場規模：用途別分析（血友病、後天性血友病、第VII因子欠乏症、グランツマン血栓症（GT））
- 世界のエプタコグアルファ（rFVIIa）市場規模予測（2018年-2029年）
- エプタコグアルファ（rFVIIa）の平均価格推移（2018年-2029年）
- 前提条件と制限事項

・メーカー別競争状況
- メーカー別市場シェア
- 世界の主要メーカー、業界ランキング分析
- メーカー別平均価格
- エプタコグアルファ（rFVIIa）市場の競争状況およびトレンド

・エプタコグアルファ（rFVIIa）の地域別市場規模
- 北米のエプタコグアルファ（rFVIIa）市場規模（2018年-2029年）
- 米国のエプタコグアルファ（rFVIIa）市場規模（2018年-2029年）
- ヨーロッパのエプタコグアルファ（rFVIIa）市場規模（2018年-2029年）
- アジア太平洋のエプタコグアルファ（rFVIIa）市場規模（2018年-2029年）
- 中国のエプタコグアルファ（rFVIIa）市場規模（2018年-2029年）
- 日本のエプタコグアルファ（rFVIIa）市場規模（2018年-2029年）
- 韓国のエプタコグアルファ（rFVIIa）市場規模（2018年-2029年）
- インドのエプタコグアルファ（rFVIIa）市場規模（2018年-2029年）
- オーストラリアのエプタコグアルファ（rFVIIa）市場規模（2018年-2029年）
- 中南米のエプタコグアルファ（rFVIIa）市場規模（2018年-2029年）
- 中東・アフリカのエプタコグアルファ（rFVIIa）市場規模（2018年-2029年）

・種類別セグメント：凍結乾燥製剤、凍結乾燥粉体
- 世界のエプタコグアルファ（rFVIIa）のタイプ別販売量（2018年-2023年）
- 世界のエプタコグアルファ（rFVIIa）のタイプ別売上（2018年-2023年）
- 世界のエプタコグアルファ（rFVIIa）のタイプ別価格

・用途別セグメント：血友病、後天性血友病、第VII因子欠乏症、グランツマン血栓症（GT）
- 世界のエプタコグアルファ（rFVIIa）の用途別販売量（2018年-2023年）
- 世界のエプタコグアルファ（rFVIIa）の用途別売上（2018年-2023年）
- 世界のエプタコグアルファ（rFVIIa）の用途別価格

・主要企業のプロファイル：企業情報、事業概要、売上、製品ポートフォリオ、動向
Novo Nordisk、LFB SA、GENERIUM、Northland-bio、CSL、Shire (Takeda)、Bayer

・産業チェーンと販売チャネルの分析
- エプタコグアルファ（rFVIIa）産業チェーン分析
- エプタコグアルファ（rFVIIa）の主要原材料
- エプタコグアルファ（rFVIIa）の販売チャネル
- エプタコグアルファ（rFVIIa）のディストリビューター
- エプタコグアルファ（rFVIIa）の主要顧客

・エプタコグアルファ（rFVIIa）市場ダイナミクス
- エプタコグアルファ（rFVIIa）の業界動向
- エプタコグアルファ（rFVIIa）市場の成長ドライバ、課題、阻害要因

・調査の結論

・調査手法と情報源

Recombinant human coagulation factor VIIa is a drug from Novo Nordisk for bleeding episodes and prevention of bleeding during surgical procedures or invasive procedures in the following patient groups:
1. Inhibitors of coagulation factor VIII or IX 5BU in congenital hemophilia patients; 2. Congenital hemophilia patients who are expected to have a high memory response to injection of coagulation factor VIII or coagulation factor IX; 3. Acquired blood 4. Patients with congenital FVII deficiency; 5. Patients with thrombocytopenia who have GP IIb-IIIa and/or HLA antibodies and past or present ineffective or poor platelet transfusions.
Highlights
The global Eptacog Alfa (rFVIIa) market was valued at US$ 1190 million in 2022 and is anticipated to reach US$ 1654.2 million by 2029, witnessing a CAGR of 4.6% during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
Novo Nordisk is the largest manufacturers of eptacog alfa (rFVIIa) in the world, has a share about 92%. Other players include LFB SA, GENERIUM,Northland-bio, and Northland-bioi, etc. The key players are mainly located in Europe, North America, China, and Japan. In terms of product, freeze-dried preparation is the largest segment, with a share over 52%. And in terms of application, the largest application is hemophilia, with a share over 48%, followed by acquired hemophilia.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Eptacog Alfa (rFVIIa), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Eptacog Alfa (rFVIIa).
The Eptacog Alfa (rFVIIa) market size, estimations, and forecasts are provided in terms of sales volume (g) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Eptacog Alfa (rFVIIa) market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Eptacog Alfa (rFVIIa) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Novo Nordisk
LFB SA
GENERIUM
Northland-bio
CSL
Shire (Takeda)
Bayer
Segment by Type
Freeze-dried Preparation
Freeze-dried Powder
Segment by Application
Hemophilia
Acquired Hemophilia
Factor VII Deficiency
Glanzmann Thrombasthenia (GT)
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Eptacog Alfa (rFVIIa) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Eptacog Alfa (rFVIIa) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Eptacog Alfa (rFVIIa) market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Eptacog Alfa (rFVIIa) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Eptacog Alfa (rFVIIa) and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Eptacog Alfa (rFVIIa) industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Eptacog Alfa (rFVIIa).
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Eptacog Alfa (rFVIIa) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Eptacog Alfa (rFVIIa) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Analysis of sales channel, distributors and customers
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: sales and revenue forecast, global and regional, by Type and by Application. It provides a quantitative analysis of the market size and development potential of each market segment in the next six years.
Chapter 11: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Eptacog Alfa (rFVIIa) Market Overview
1.1 Product Overview and Scope of Eptacog Alfa (rFVIIa)
1.2 Eptacog Alfa (rFVIIa) Segment by Type
1.2.1 Global Eptacog Alfa (rFVIIa) Market Value Comparison by Type (2023-2029)
1.2.2 Freeze-dried Preparation
1.2.3 Freeze-dried Powder
1.3 Eptacog Alfa (rFVIIa) Segment by Application
1.3.1 Global Eptacog Alfa (rFVIIa) Market Value by Application: (2023-2029)
1.3.2 Hemophilia
1.3.3 Acquired Hemophilia
1.3.4 Factor VII Deficiency
1.3.5 Glanzmann Thrombasthenia (GT)
1.4 Global Eptacog Alfa (rFVIIa) Market Size Estimates and Forecasts
1.4.1 Global Eptacog Alfa (rFVIIa) Revenue 2018-2029
1.4.2 Global Eptacog Alfa (rFVIIa) Sales 2018-2029
1.4.3 Global Eptacog Alfa (rFVIIa) Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Eptacog Alfa (rFVIIa) Market Competition by Manufacturers
2.1 Global Eptacog Alfa (rFVIIa) Sales Market Share by Manufacturers (2018-2023)
2.2 Global Eptacog Alfa (rFVIIa) Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Eptacog Alfa (rFVIIa) Average Price by Manufacturers (2018-2023)
2.4 Global Eptacog Alfa (rFVIIa) Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Eptacog Alfa (rFVIIa), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Eptacog Alfa (rFVIIa), Product Type & Application
2.7 Eptacog Alfa (rFVIIa) Market Competitive Situation and Trends
2.7.1 Eptacog Alfa (rFVIIa) Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Eptacog Alfa (rFVIIa) Players Market Share by Revenue
2.7.3 Global Eptacog Alfa (rFVIIa) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Eptacog Alfa (rFVIIa) Retrospective Market Scenario by Region
3.1 Global Eptacog Alfa (rFVIIa) Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Eptacog Alfa (rFVIIa) Global Eptacog Alfa (rFVIIa) Sales by Region: 2018-2029
3.2.1 Global Eptacog Alfa (rFVIIa) Sales by Region: 2018-2023
3.2.2 Global Eptacog Alfa (rFVIIa) Sales by Region: 2024-2029
3.3 Global Eptacog Alfa (rFVIIa) Global Eptacog Alfa (rFVIIa) Revenue by Region: 2018-2029
3.3.1 Global Eptacog Alfa (rFVIIa) Revenue by Region: 2018-2023
3.3.2 Global Eptacog Alfa (rFVIIa) Revenue by Region: 2024-2029
3.4 North America Eptacog Alfa (rFVIIa) Market Facts & Figures by Country
3.4.1 North America Eptacog Alfa (rFVIIa) Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Eptacog Alfa (rFVIIa) Sales by Country (2018-2029)
3.4.3 North America Eptacog Alfa (rFVIIa) Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Eptacog Alfa (rFVIIa) Market Facts & Figures by Country
3.5.1 Europe Eptacog Alfa (rFVIIa) Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Eptacog Alfa (rFVIIa) Sales by Country (2018-2029)
3.5.3 Europe Eptacog Alfa (rFVIIa) Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Eptacog Alfa (rFVIIa) Market Facts & Figures by Country
3.6.1 Asia Pacific Eptacog Alfa (rFVIIa) Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Eptacog Alfa (rFVIIa) Sales by Country (2018-2029)
3.6.3 Asia Pacific Eptacog Alfa (rFVIIa) Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Eptacog Alfa (rFVIIa) Market Facts & Figures by Country
3.7.1 Latin America Eptacog Alfa (rFVIIa) Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Eptacog Alfa (rFVIIa) Sales by Country (2018-2029)
3.7.3 Latin America Eptacog Alfa (rFVIIa) Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Eptacog Alfa (rFVIIa) Market Facts & Figures by Country
3.8.1 Middle East and Africa Eptacog Alfa (rFVIIa) Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Eptacog Alfa (rFVIIa) Sales by Country (2018-2029)
3.8.3 Middle East and Africa Eptacog Alfa (rFVIIa) Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Eptacog Alfa (rFVIIa) Sales by Type (2018-2029)
4.1.1 Global Eptacog Alfa (rFVIIa) Sales by Type (2018-2023)
4.1.2 Global Eptacog Alfa (rFVIIa) Sales by Type (2024-2029)
4.1.3 Global Eptacog Alfa (rFVIIa) Sales Market Share by Type (2018-2029)
4.2 Global Eptacog Alfa (rFVIIa) Revenue by Type (2018-2029)
4.2.1 Global Eptacog Alfa (rFVIIa) Revenue by Type (2018-2023)
4.2.2 Global Eptacog Alfa (rFVIIa) Revenue by Type (2024-2029)
4.2.3 Global Eptacog Alfa (rFVIIa) Revenue Market Share by Type (2018-2029)
4.3 Global Eptacog Alfa (rFVIIa) Price by Type (2018-2029)
5 Segment by Application
5.1 Global Eptacog Alfa (rFVIIa) Sales by Application (2018-2029)
5.1.1 Global Eptacog Alfa (rFVIIa) Sales by Application (2018-2023)
5.1.2 Global Eptacog Alfa (rFVIIa) Sales by Application (2024-2029)
5.1.3 Global Eptacog Alfa (rFVIIa) Sales Market Share by Application (2018-2029)
5.2 Global Eptacog Alfa (rFVIIa) Revenue by Application (2018-2029)
5.2.1 Global Eptacog Alfa (rFVIIa) Revenue by Application (2018-2023)
5.2.2 Global Eptacog Alfa (rFVIIa) Revenue by Application (2024-2029)
5.2.3 Global Eptacog Alfa (rFVIIa) Revenue Market Share by Application (2018-2029)
5.3 Global Eptacog Alfa (rFVIIa) Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Novo Nordisk
6.1.1 Novo Nordisk Corporation Information
6.1.2 Novo Nordisk Description and Business Overview
6.1.3 Novo Nordisk Eptacog Alfa (rFVIIa) Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Novo Nordisk Eptacog Alfa (rFVIIa) Product Portfolio
6.1.5 Novo Nordisk Recent Developments/Updates
6.2 LFB SA
6.2.1 LFB SA Corporation Information
6.2.2 LFB SA Description and Business Overview
6.2.3 LFB SA Eptacog Alfa (rFVIIa) Sales, Revenue and Gross Margin (2018-2023)
6.2.4 LFB SA Eptacog Alfa (rFVIIa) Product Portfolio
6.2.5 LFB SA Recent Developments/Updates
6.3 GENERIUM
6.3.1 GENERIUM Corporation Information
6.3.2 GENERIUM Description and Business Overview
6.3.3 GENERIUM Eptacog Alfa (rFVIIa) Sales, Revenue and Gross Margin (2018-2023)
6.3.4 GENERIUM Eptacog Alfa (rFVIIa) Product Portfolio
6.3.5 GENERIUM Recent Developments/Updates
6.4 Northland-bio
6.4.1 Northland-bio Corporation Information
6.4.2 Northland-bio Description and Business Overview
6.4.3 Northland-bio Eptacog Alfa (rFVIIa) Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Northland-bio Eptacog Alfa (rFVIIa) Product Portfolio
6.4.5 Northland-bio Recent Developments/Updates
6.5 CSL
6.5.1 CSL Corporation Information
6.5.2 CSL Description and Business Overview
6.5.3 CSL Eptacog Alfa (rFVIIa) Sales, Revenue and Gross Margin (2018-2023)
6.5.4 CSL Eptacog Alfa (rFVIIa) Product Portfolio
6.5.5 CSL Recent Developments/Updates
6.6 Shire (Takeda)
6.6.1 Shire (Takeda) Corporation Information
6.6.2 Shire (Takeda) Description and Business Overview
6.6.3 Shire (Takeda) Eptacog Alfa (rFVIIa) Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Shire (Takeda) Eptacog Alfa (rFVIIa) Product Portfolio
6.6.5 Shire (Takeda) Recent Developments/Updates
6.7 Bayer
6.6.1 Bayer Corporation Information
6.6.2 Bayer Description and Business Overview
6.6.3 Bayer Eptacog Alfa (rFVIIa) Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Bayer Eptacog Alfa (rFVIIa) Product Portfolio
6.7.5 Bayer Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Eptacog Alfa (rFVIIa) Industry Chain Analysis
7.2 Eptacog Alfa (rFVIIa) Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Eptacog Alfa (rFVIIa) Production Mode & Process
7.4 Eptacog Alfa (rFVIIa) Sales and Marketing
7.4.1 Eptacog Alfa (rFVIIa) Sales Channels
7.4.2 Eptacog Alfa (rFVIIa) Distributors
7.5 Eptacog Alfa (rFVIIa) Customers
8 Eptacog Alfa (rFVIIa) Market Dynamics
8.1 Eptacog Alfa (rFVIIa) Industry Trends
8.2 Eptacog Alfa (rFVIIa) Market Drivers
8.3 Eptacog Alfa (rFVIIa) Market Challenges
8.4 Eptacog Alfa (rFVIIa) Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Tables
Table 1. Global Eptacog Alfa (rFVIIa) Market Value Comparison by Type (2023-2029) & (US$ Million)
Table 2. Global Eptacog Alfa (rFVIIa) Market Value Comparison by Application (2023-2029) & (US$ Million)
Table 3. Global Eptacog Alfa (rFVIIa) Market Competitive Situation by Manufacturers in 2022
Table 4. Global Eptacog Alfa (rFVIIa) Sales (g) of Key Manufacturers (2018-2023)
Table 5. Global Eptacog Alfa (rFVIIa) Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Eptacog Alfa (rFVIIa) Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Eptacog Alfa (rFVIIa) Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Eptacog Alfa (rFVIIa) Average Price (US$/mg) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Eptacog Alfa (rFVIIa), Industry Ranking, 2021 VS 2022 VS 2023
Table 10. Global Key Manufacturers of Eptacog Alfa (rFVIIa), Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Eptacog Alfa (rFVIIa), Product Type & Application
Table 12. Global Key Manufacturers of Eptacog Alfa (rFVIIa), Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Eptacog Alfa (rFVIIa) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Eptacog Alfa (rFVIIa) as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Eptacog Alfa (rFVIIa) Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Eptacog Alfa (rFVIIa) Sales by Region (2018-2023) & (g)
Table 18. Global Eptacog Alfa (rFVIIa) Sales Market Share by Region (2018-2023)
Table 19. Global Eptacog Alfa (rFVIIa) Sales by Region (2024-2029) & (g)
Table 20. Global Eptacog Alfa (rFVIIa) Sales Market Share by Region (2024-2029)
Table 21. Global Eptacog Alfa (rFVIIa) Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Eptacog Alfa (rFVIIa) Revenue Market Share by Region (2018-2023)
Table 23. Global Eptacog Alfa (rFVIIa) Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Eptacog Alfa (rFVIIa) Revenue Market Share by Region (2024-2029)
Table 25. North America Eptacog Alfa (rFVIIa) Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Eptacog Alfa (rFVIIa) Sales by Country (2018-2023) & (g)
Table 27. North America Eptacog Alfa (rFVIIa) Sales by Country (2024-2029) & (g)
Table 28. North America Eptacog Alfa (rFVIIa) Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Eptacog Alfa (rFVIIa) Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Eptacog Alfa (rFVIIa) Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Eptacog Alfa (rFVIIa) Sales by Country (2018-2023) & (g)
Table 32. Europe Eptacog Alfa (rFVIIa) Sales by Country (2024-2029) & (g)
Table 33. Europe Eptacog Alfa (rFVIIa) Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Eptacog Alfa (rFVIIa) Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Eptacog Alfa (rFVIIa) Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Eptacog Alfa (rFVIIa) Sales by Region (2018-2023) & (g)
Table 37. Asia Pacific Eptacog Alfa (rFVIIa) Sales by Region (2024-2029) & (g)
Table 38. Asia Pacific Eptacog Alfa (rFVIIa) Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Eptacog Alfa (rFVIIa) Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Eptacog Alfa (rFVIIa) Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Eptacog Alfa (rFVIIa) Sales by Country (2018-2023) & (g)
Table 42. Latin America Eptacog Alfa (rFVIIa) Sales by Country (2024-2029) & (g)
Table 43. Latin America Eptacog Alfa (rFVIIa) Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Eptacog Alfa (rFVIIa) Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Eptacog Alfa (rFVIIa) Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Eptacog Alfa (rFVIIa) Sales by Country (2018-2023) & (g)
Table 47. Middle East & Africa Eptacog Alfa (rFVIIa) Sales by Country (2024-2029) & (g)
Table 48. Middle East & Africa Eptacog Alfa (rFVIIa) Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Eptacog Alfa (rFVIIa) Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Eptacog Alfa (rFVIIa) Sales (g) by Type (2018-2023)
Table 51. Global Eptacog Alfa (rFVIIa) Sales (g) by Type (2024-2029)
Table 52. Global Eptacog Alfa (rFVIIa) Sales Market Share by Type (2018-2023)
Table 53. Global Eptacog Alfa (rFVIIa) Sales Market Share by Type (2024-2029)
Table 54. Global Eptacog Alfa (rFVIIa) Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Eptacog Alfa (rFVIIa) Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Eptacog Alfa (rFVIIa) Revenue Market Share by Type (2018-2023)
Table 57. Global Eptacog Alfa (rFVIIa) Revenue Market Share by Type (2024-2029)
Table 58. Global Eptacog Alfa (rFVIIa) Price (US$/mg) by Type (2018-2023)
Table 59. Global Eptacog Alfa (rFVIIa) Price (US$/mg) by Type (2024-2029)
Table 60. Global Eptacog Alfa (rFVIIa) Sales (g) by Application (2018-2023)
Table 61. Global Eptacog Alfa (rFVIIa) Sales (g) by Application (2024-2029)
Table 62. Global Eptacog Alfa (rFVIIa) Sales Market Share by Application (2018-2023)
Table 63. Global Eptacog Alfa (rFVIIa) Sales Market Share by Application (2024-2029)
Table 64. Global Eptacog Alfa (rFVIIa) Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Eptacog Alfa (rFVIIa) Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Eptacog Alfa (rFVIIa) Revenue Market Share by Application (2018-2023)
Table 67. Global Eptacog Alfa (rFVIIa) Revenue Market Share by Application (2024-2029)
Table 68. Global Eptacog Alfa (rFVIIa) Price (US$/mg) by Application (2018-2023)
Table 69. Global Eptacog Alfa (rFVIIa) Price (US$/mg) by Application (2024-2029)
Table 70. Novo Nordisk Corporation Information
Table 71. Novo Nordisk Description and Business Overview
Table 72. Novo Nordisk Eptacog Alfa (rFVIIa) Sales (g), Revenue (US$ Million), Price (US$/mg) and Gross Margin (2018-2023)
Table 73. Novo Nordisk Eptacog Alfa (rFVIIa) Product
Table 74. Novo Nordisk Recent Developments/Updates
Table 75. LFB SA Corporation Information
Table 76. LFB SA Description and Business Overview
Table 77. LFB SA Eptacog Alfa (rFVIIa) Sales (g), Revenue (US$ Million), Price (US$/mg) and Gross Margin (2018-2023)
Table 78. LFB SA Eptacog Alfa (rFVIIa) Product
Table 79. LFB SA Recent Developments/Updates
Table 80. GENERIUM Corporation Information
Table 81. GENERIUM Description and Business Overview
Table 82. GENERIUM Eptacog Alfa (rFVIIa) Sales (g), Revenue (US$ Million), Price (US$/mg) and Gross Margin (2018-2023)
Table 83. GENERIUM Eptacog Alfa (rFVIIa) Product
Table 84. GENERIUM Recent Developments/Updates
Table 85. Northland-bio Corporation Information
Table 86. Northland-bio Description and Business Overview
Table 87. Northland-bio Eptacog Alfa (rFVIIa) Sales (g), Revenue (US$ Million), Price (US$/mg) and Gross Margin (2018-2023)
Table 88. Northland-bio Eptacog Alfa (rFVIIa) Product
Table 89. Northland-bio Recent Developments/Updates
Table 90. CSL Corporation Information
Table 91. CSL Description and Business Overview
Table 92. CSL Eptacog Alfa (rFVIIa) Sales (g), Revenue (US$ Million), Price (US$/mg) and Gross Margin (2018-2023)
Table 93. CSL Eptacog Alfa (rFVIIa) Product
Table 94. CSL Recent Developments/Updates
Table 95. Shire (Takeda) Corporation Information
Table 96. Shire (Takeda) Description and Business Overview
Table 97. Shire (Takeda) Eptacog Alfa (rFVIIa) Sales (g), Revenue (US$ Million), Price (US$/mg) and Gross Margin (2018-2023)
Table 98. Shire (Takeda) Eptacog Alfa (rFVIIa) Product
Table 99. Shire (Takeda) Recent Developments/Updates
Table 100. Bayer Corporation Information
Table 101. Bayer Description and Business Overview
Table 102. Bayer Eptacog Alfa (rFVIIa) Sales (g), Revenue (US$ Million), Price (US$/mg) and Gross Margin (2018-2023)
Table 103. Bayer Eptacog Alfa (rFVIIa) Product
Table 104. Bayer Recent Developments/Updates
Table 105. Key Raw Materials Lists
Table 106. Raw Materials Key Suppliers Lists
Table 107. Eptacog Alfa (rFVIIa) Distributors List
Table 108. Eptacog Alfa (rFVIIa) Customers List
Table 109. Eptacog Alfa (rFVIIa) Market Trends
Table 110. Eptacog Alfa (rFVIIa) Market Drivers
Table 111. Eptacog Alfa (rFVIIa) Market Challenges
Table 112. Eptacog Alfa (rFVIIa) Market Restraints
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Eptacog Alfa (rFVIIa)
Figure 2. Global Eptacog Alfa (rFVIIa) Market Value Comparison by Type (2023-2029) & (US$ Million)
Figure 3. Global Eptacog Alfa (rFVIIa) Market Share by Type in 2022 & 2029
Figure 4. Freeze-dried Preparation Product Picture
Figure 5. Freeze-dried Powder Product Picture
Figure 6. Global Eptacog Alfa (rFVIIa) Market Value Comparison by Application (2023-2029) & (US$ Million)
Figure 7. Global Eptacog Alfa (rFVIIa) Market Share by Application in 2022 & 2029
Figure 8. Hemophilia
Figure 9. Acquired Hemophilia
Figure 10. Factor VII Deficiency
Figure 11. Glanzmann Thrombasthenia (GT)
Figure 12. Global Eptacog Alfa (rFVIIa) Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 13. Global Eptacog Alfa (rFVIIa) Market Size (2018-2029) & (US$ Million)
Figure 14. Global Eptacog Alfa (rFVIIa) Sales (2018-2029) & (g)
Figure 15. Global Eptacog Alfa (rFVIIa) Average Price (US$/mg) & (2018-2029)
Figure 16. Eptacog Alfa (rFVIIa) Report Years Considered
Figure 17. Eptacog Alfa (rFVIIa) Sales Share by Manufacturers in 2022
Figure 18. Global Eptacog Alfa (rFVIIa) Revenue Share by Manufacturers in 2022
Figure 19. The Global 5 and 10 Largest Eptacog Alfa (rFVIIa) Players: Market Share by Revenue in 2022
Figure 20. Eptacog Alfa (rFVIIa) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 21. Global Eptacog Alfa (rFVIIa) Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 22. North America Eptacog Alfa (rFVIIa) Sales Market Share by Country (2018-2029)
Figure 23. North America Eptacog Alfa (rFVIIa) Revenue Market Share by Country (2018-2029)
Figure 24. United States Eptacog Alfa (rFVIIa) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 25. Canada Eptacog Alfa (rFVIIa) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 26. Europe Eptacog Alfa (rFVIIa) Sales Market Share by Country (2018-2029)
Figure 27. Europe Eptacog Alfa (rFVIIa) Revenue Market Share by Country (2018-2029)
Figure 28. Germany Eptacog Alfa (rFVIIa) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. France Eptacog Alfa (rFVIIa) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. U.K. Eptacog Alfa (rFVIIa) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. Italy Eptacog Alfa (rFVIIa) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. Russia Eptacog Alfa (rFVIIa) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. Asia Pacific Eptacog Alfa (rFVIIa) Sales Market Share by Region (2018-2029)
Figure 34. Asia Pacific Eptacog Alfa (rFVIIa) Revenue Market Share by Region (2018-2029)
Figure 35. China Eptacog Alfa (rFVIIa) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. Japan Eptacog Alfa (rFVIIa) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. South Korea Eptacog Alfa (rFVIIa) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. India Eptacog Alfa (rFVIIa) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. Australia Eptacog Alfa (rFVIIa) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. China Taiwan Eptacog Alfa (rFVIIa) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Indonesia Eptacog Alfa (rFVIIa) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Thailand Eptacog Alfa (rFVIIa) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Malaysia Eptacog Alfa (rFVIIa) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Latin America Eptacog Alfa (rFVIIa) Sales Market Share by Country (2018-2029)
Figure 45. Latin America Eptacog Alfa (rFVIIa) Revenue Market Share by Country (2018-2029)
Figure 46. Mexico Eptacog Alfa (rFVIIa) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Brazil Eptacog Alfa (rFVIIa) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Argentina Eptacog Alfa (rFVIIa) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Middle East & Africa Eptacog Alfa (rFVIIa) Sales Market Share by Country (2018-2029)
Figure 50. Middle East & Africa Eptacog Alfa (rFVIIa) Revenue Market Share by Country (2018-2029)
Figure 51. Turkey Eptacog Alfa (rFVIIa) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. Saudi Arabia Eptacog Alfa (rFVIIa) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. UAE Eptacog Alfa (rFVIIa) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. Global Sales Market Share of Eptacog Alfa (rFVIIa) by Type (2018-2029)
Figure 55. Global Revenue Market Share of Eptacog Alfa (rFVIIa) by Type (2018-2029)
Figure 56. Global Eptacog Alfa (rFVIIa) Price (US$/mg) by Type (2018-2029)
Figure 57. Global Sales Market Share of Eptacog Alfa (rFVIIa) by Application (2018-2029)
Figure 58. Global Revenue Market Share of Eptacog Alfa (rFVIIa) by Application (2018-2029)
Figure 59. Global Eptacog Alfa (rFVIIa) Price (US$/mg) by Application (2018-2029)
Figure 60. Eptacog Alfa (rFVIIa) Value Chain
Figure 61. Eptacog Alfa (rFVIIa) Production Process
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Distributors Profiles
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 舌安定装置（TSD）の世界市場2023年：<50$、50-100$、>100$
  • 薬剤溶出バルーン（DEB）の世界市場2023年：末梢DEB、冠動脈DEB
  • 自家調整検査（LDT）の世界市場2023年：臨床生化学、血液学、免疫学、分子診断学、その他
  • 円形ホッチキスカーブ（CSC）の世界市場2023年：外径：20mm以下、外径：20mm～25mm、外径：25mm以上
  • ジアセトンアルコール（DAA）の世界市場2023年：0.98、0.99、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(QYR23MA8754 )"エプタコグアルファ（rFVIIa）の世界市場2023年：凍結乾燥製剤、凍結乾燥粉体" (英文：Global Eptacog Alfa (rFVIIa) Market Research Report 2023)はQYResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。